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Amyotrophic lateral sclerosis (ALS) is a devastating neurological disorder characterized by the degeneration of motor neurons and typi-
cally results in death within 3–5 years from onset. Familial ALS (FALS) comprises 5%–10% of ALS cases, and the identification of genes
associated with FALS is indispensable to elucidating the molecular pathogenesis. We identified a Japanese family affected by late-onset,
autosomal-dominant ALS in which mutations in genes known to be associated with FALS were excluded. A whole- genome sequencing
and parametric linkage analysis under the assumption of an autosomal-dominant mode of inheritance with incomplete penetrance re-
vealed the mutation c.2780G>A (p. Arg927Gln) in ERBB4. An extensive mutational analysis revealed the same mutation in a Canadian
individual with familial ALS and a de novo mutation, c.3823C>T (p. Arg1275Trp), in a Japanese simplex case. These amino acid substi-
tutions involve amino acids highly conserved among species, are predicted as probably damaging, and are located within a tyrosine ki-
nase domain (p. Arg927Gln) or a C-terminal domain (p. Arg1275Trp), both of which mediate essential functions of ErbB4 as a receptor
tyrosine kinase. Functional analysis revealed that these mutations led to a reduced autophosphorylation of ErbB4 upon neuregulin-1
(NRG-1) stimulation. Clinical presentations of the individuals with mutations were characterized by the involvement of both upper
and lower motor neurons, a lack of obvious cognitive dysfunction, and relatively slow progression. This study indicates that disruption
of the neuregulin-ErbB4 pathway is involved in the pathogenesis of ALS and potentially paves the way for the development of innova-
tive therapeutic strategies such using NRGs or their agonists to upregulate ErbB4 functions.Amyotrophic lateral sclerosis (ALS) is a devastating
neurological disorder in which the degeneration of motor
neurons leads to progressive weakness and wasting of
limb, bulbar, and respiratory muscles. Familial ALS
(FALS) comprises 5%–10% of ALS cases, and the
remaining cases are simplex cases of ALS (SALS). To
date, more than 20 genes have been shown to be
associated with ALS,1 and these account for 75% of
FALS and 14% of SALS cases.2 Mutations that are
found in FALS-associated genes but that are also identified
in individuals with SALS are considered mutations
with reduced penetrance or de novo mutations. Further
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and SALS.
Identification of genes associated with familial diseases
has been accomplished through identification of the dis-
ease loci on the chromosomes by linkage analysis of large
pedigrees and subsequent positional cloning of the genes.
The majority of the FALS pedigrees, however, are not large
and do not have multiple affected members as a result of
the poor prognosis of the disease and the late age of onset,
which makes it difficult to sufficiently narrow the candi-
date regions by linkage analyses and means that it takes a
tremendous effort to identify the genes associated with
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Figure 1. Pedigrees of ALS and Charac-
terization of Mutations
(A) Pedigree charts of the index family.
Filled symbols indicate affected individ-
uals. The arrow indicates the proband.
For confidentiality purposes, all unaffected
siblings are indicated by diamonds. Dots or
asterisks indicate individuals included in
the linkage study or WGS, respectively.
Age at present or age at death is shown un-
der each individual, and ages at onset are
shown in parentheses. The box with gray
shading indicates that the individual’s
clinical information obtained from the
family members strongly supports the
diagnosis of ALS, although detailed neuro-
logical evaluations have not been conduct-
ed for this individual.
(B) Additional Canadian (Ped255) and
Japanese (Ped5175) pedigrees with ERBB4
mutations. The electropherograms of mu-
tational data are shown beside each
member. Nucleotide colors correspond to
the colors in the electropherograms. The
amino acids are designated below the
nucleotide sequences. The blue arrows
indicate the nucleotide positions of the
mutations. In the electropherograms
(Ped5175), nucleotide sequences of the
reverse complementary strand are shown.
(C) Amino acid conservation. The amino
acids Arg927 and Arg1275 are highly
conserved among species.
(D) The protein structure along with the
locations of amino acid substitutions are
shown; amino acid substitutions are indi-
cated by arrows. The amino acid substitu-
tion p. Arg927Gln resides in the tyrosine
kinase domain, which mediates the key
functions of ErbB4. The amino acid substi-
tution p. Arg1275Trp resides in the
C-terminal domain in the vicinity of mul-
tiple phosphorylation sites, whichmediate
downstream signaling pathways.sequencing technologies has allowed us to overcome the
difficulty by means of whole-genome sequencing (WGS)
or exome analysis.
We identified a Japanese family with three affected
siblings presenting with late-onset ALS (Figure 1A and Ta-
ble 1). The familial history indicated that the mode of
inheritance is probably an autosomal-dominant one.
Mutational analysis of the proband (II-4) employing direct
nucleotide sequence analysis, a microarray-based rese-
quencing, or a repeat-primed PCR analysis excluded
SOD1[MIM 147450], ALS2[MIM 606352], DCTN1[MIM
601143], CHMP2B[MIM 609512], ANG[MIM 105850],
TARDBP[MIM 605078], FUS[MIM 137070] and C9ORF72
[MIM 1614260] as the genes associated with FALS.3,4 To
identify a gene associated with FALS, we applied WGS in
combination with a linkage analysis to the pedigree. Writ-
ten informed consent was obtained from all the partici-
pants. This study was approved by the institutional review
board at the University of Tokyo.The AmericanWGS was performed on three individuals (I-2, II-3 and
II-4, as shown in Figure 1A) in the index pedigree. Paired-
end DNA libraries were generated and subjected to
massively parallel sequencing with a GAII Illumina
Genome Analyzer in accordance with the manufacturer’s
instructions. The short read sequences obtained were
aligned to the reference genome (NCBI37/hg19 assembly)
via the Burrows-Wheeler Aligner.5 Downstream analyses in
which potential PCR duplicates were removed were pro-
cessed with SAMtools.6 Aligned reads were viewed on an
Integrative Genomics Viewer.7 Genomic sequence varia-
tions were identified with the SAMtools pileup command
and annotated with Refseq, dbSNP135, 1000 Genomes,
personal genome databases, the NHLBI GO Exome
Sequencing Project (NHLBI-ESP) database, and an in-house
variant database containing 41 whole genomes and 1,408
exomes in the Japanese population. The numbers of non-
synonymous variants that were identified in individuals
I-2, II-3, and II-4 but that were not present in any of theJournal of Human Genetics 93, 900–905, November 7, 2013 901
Table 1. Clinical Characteristics of Affected Individuals
Pedigree Number Pedigree 3166 Pedigree 255 Pedigree 5175
Ethnicity Japanese Canadian Japanese
Inheritance familial (autosomal dominant) familial
(autosomal dominant)
simplex
Mutation c.2780G>A c.2780G>A c.3823C>T
Amino acid
substitution
p. Arg927Gln p. Arg927Gln p. Arg1275Trp
Members I-1 II-3 II-4 (proband) II-6 III-3 II-1
Age at onset 70 60 63 60 67 45
Initial symptoms bulbar N.D. upper limbs respiration upper limbs upper limbs
Diagnostic criteriaa N.D. N.D. definite definite probable probable
Progression unable to walk
after 3 years
ventilator -dependent
after 5 years, locked-in
state after 8 years
locked-in state
after 5 years
ventilator- dependent
after 1 year, locked-in
state after 5 years
slow progression
that significantly
decelerated and finally
stopped after 8 years
wheelchair- bound,
MRS 1-2/5 in upper
extremities after 5
years
Cognitive function N.D. N.D. normal normal N.D. normal
Age at death 74 69 70 66 N/A N/A
Abbreviations are as follows: N.D., not described; MRS, manual muscle testing rating scale; and N/A, not applicable.
aEl Escorial and Airlie House revised criteria.databases (hereafter, variants not found in the databases
are referred to as ‘‘novel’’) were 411, 404, and 382, respec-
tively (Table S1). No novel nonsynonymous variants in
genes known to be associated with FALS were included.
Among the identified variants, 57 were identified both in
the proband and in the affected sibling, but not in the
mother, and were subjected to further analysis.
The individuals indicated by dots in Figure 1A were gen-
otyped with Genome-Wide Human SNPArray 6.0 (Affyme-
trix). Linkage analysis and haplotype reconstruction were
conducted with the pipeline software SNP-HiTLink8 and
Allegro version 29 under the assumption of an auto-
somal-dominant mode of inheritance and a disease-allele
frequency of 0.000001. Parametric multipoint linkage
analysis under the assumption of complete penetrance re-
vealed three loci spanning 23.6 Mb on chromosomes 1, 6,
and 13, having a maximum LOD score of 1.8 (Figure S1;
penetrance ¼ 1.0), and containing 88 annotated genes.
However, no novel nonsynonymous variants were identi-
fied in the candidate regions. We then considered the pos-
sibility of reduced penetrance. When penetrance was
reduced to 0.8 (Figure S1), seven additional loci had LOD
scores> 0.7 and were thus shown to support linkage; these
loci contained 809 annotated genes. Three heterozygous
novel nonsynonymous variants were identified in these
regions; among these variants, only c.2780G>A (p.
Arg927Gln; dbSNP SubSNP ID ss831884245) substituting
glutamine for arginine at codon 927 (p. Arg927Gln) in v-
erb-a erythroblastic leukemia viral oncogene homolog 4
(avian) (ERBB4 [MIM 600543; RefSeq accession number
NM_005235.2]) was not present in 477 controls (Table
S2). When we allowed further reduced penetrance, we
identified 19 additional loci with LOD > 0; these loci con-902 The American Journal of Human Genetics 93, 900–905, Novembtained 1,265 annotated genes. In these regions, we
identified seven heterozygous novel nonsynonymous
variants, among which three variants in OR2D3
(RefSeq NM_001004684.1), FTCD (MIM 606806; RefSeq
NM_206965.1), and TJP2 (MIM 607709; RefSeq
NM_001170414.2) were not present in 477 controls (Table
S2). OR2D3 is an olfactory receptor gene; the substituted
amino acid in OR2D3 is not conserved, and the substitu-
tion is predicted as benign by PolyPhen-2 analysis. FTCD
and TJP2 are associated with autosomal-recessive gluta-
mate formiminotransferase deficiency (MIM 229100) and
familial hypercholanemia (MIM 607748), respectively,
and heterozygous carriers have not been described as
exhibiting ALS. Taken together, the results pointed to
c.2780G>A in ERBB4 as the most likely pathogenic muta-
tion.
We used a direct nucleotide sequence analysis method
to conduct mutational analysis of ERBB4 in 364 FALS
and 818 SALS individuals by using an ABI 3100 sequencer
and BigDye Terminator ver3.1 (Applied Biosystems). We
used the ExonPrimer website to design oligonucleotide
primers (Table S3). The mutation c.2780G>A was also
identified in one Canadian FALS individual (Figure 1B).
Unfortunately, DNA from other family members was not
available to confirm segregation. To investigate a possibil-
ity that the c.2780G>A mutation identified in the
Japanese and Canadian families is a common founder
mutation, we compared the haplotypes with the
c.2780G>A mutation in ERBB4 of the Japanese and Cana-
dian families (Figure S2). Different SNPs were observed 14
kbp and 5 kbp centromeric and telomeric to the mutation,
respectively, indicating that disease haplotypes of the Jap-
anese and Canadian families are different and thater 7, 2013
Figure 2. Functional Analysis of Wild-Type and Mutant ErbB4
upon Neuregulin-1 Stimulation
COS-7 cells transfected with an empty-vector control or plasmids
encoding either wild-type (wt) or mutant HA-tagged ErbB4 (p.
Arg114Gln, p. Ala158Glu, p. His374Gln, p. Arg927Gln, or p.
Arg1275Trp) were stimulated with or without NRG-1, and the au-
tophosphorylation activity of ErbB4 was analyzed by immunoblot
analysis with antibodies against phospho-ErbB4 (Tyr1284) (Cell
Signaling) and HA tag (Abcam), respectively. For loading controls,
immunoblotting was performed with an anti-actin antibody
(Santa Cruz Biotechnology). Three amino acid substitutions,
including p.Arg114Gln, p.Ala158Glu, and p.His374Gln
(rs760369), identified through mutational analysis of FALS and
SALS individuals, were included in autophosphorylation assay.
The substitutions p.Arg114Gln and p.Ala158Glu were not consid-
ered to be relevant to ALS because neither recurrence nor cosegre-
gation was confirmed.mutation occurred independently. We identified a de novo
mutation of c.3823C>T (dbSNP SubSNP ID ss831884246),
substituting tryptophan for arginine at codon 1275 (p.
Arg1275Trp), in a Japanese SALS individual (Figure 1B) in
whom a biological parent-descendant relationship was
confirmed (Table S4) by the PLINK10 algorithm. These mu-
tations were neither present in the 477 Japanese controls
nor registered in the in-house database containing 41
whole genomes and 1408 exomes, the 1000 Genomes
database, or the NHLBI-ESP database, containing 6503
exomes. Furthermore, c.2780G>A was not present in 190
Canadian controls. The identification of c.2780G>A in
two independent families of different ethnic backgrounds
strongly supported c.2780G>A as the causative mutation
for ALS. Given that de novo mutation rates have been esti-
mated to be 1.20 3 108 per nucleotide per generation11
and less than one nonsynonymous single-nucleotide
variant (SNV)/generation,12 the observation of the de
novo mutation further supports the idea that c.3823C>T
is likely to be the causative mutation for ALS in this indi-
vidual. The mutation’s substituted arginine residues,
Arg927 and Arg1275, are highly conserved among species
(Figure 1C), and the substitutions are predicted to be prob-
ably damaging by PolyPhen-2 analysis. The amino acid res-
idue Arg927 resides in a tyrosine kinase domain, which is
essential for the receptor tyrosine kinase activity, and
Arg1275 is located in a C-terminal domain in the vicinityThe Americanof multiple phosphorylation sites, which mediate down-
stream signaling pathways (Figure 1D). The clinical presen-
tations of these ALS individuals with the ERBB4mutations
are summarized in Table 1. The common clinical character-
istics of the individuals included both upper and lower
motor-neuron involvement diagnosed as definite or prob-
able ALS according to El Escorial and Airlie House revised
criteria, relatively slow disease progression, and no obvious
cognitive impairment. The individuals with the
c.2780G>A mutation were characterized by relatively late
onset (the ages at onset ranged from 60–70 years) and a
slightly reduced penetrance. In contrast, the individual
with the c.3823C>T mutation was characterized by early
onset (45 years of age).
ErbB4 is a member of the epidermal growth factor (EGF)
subfamily of receptor tyrosine kinases (RTKs). It forms a
homodimer or a heterodimer with ErbB2 or ErbB3 and is
activated upon binding of neuregulins (NRGs) to the extra-
cellular ligand-binding domain of ErbB4.13 Activation of
ErbB4 is mediated by increased tyrosine kinase activity
upon NRG binding, resulting in autophosphorylation of
the C-terminal tail.14 To determine how the twomutations
identified in the ALS individuals affect ErbB4 functions, we
investigated the autophosphorylation of ErbB4 in cells
expressing either wild-type or mutant (c.2780G>A or
c.3823C>T) ERBB4 in the presence of NRG-1. The ERBB4
mutations were introduced into the pBABE-pur-
oERBB4JM-aCYT-2HA plasmid encoding HA-tagged ErbB4
JM-a CYT-215 by site-directed mutagenesis according to
the protocol described in the Phusion Site-Directed Muta-
genesis Kit (Thermo Fisher Scientific). After mutagenesis,
all the constructs were verified by sequencing. The plas-
mids were transiently transfected into COS-7 cells via
FuGENE 6 transfection reagent (Roche) in accordance
with the manufacturer’s instructions. Transfected cells
were starved of serum overnight and stimulated with 0 or
50 ng/ml NRG-1 (R&D Systems) for 10 min at 37C. After
stimulation, the cells were lysed, and samples equivalent
to 50 mg of total protein were separated through 8% SDS-
PAGE gels. For detectiin of ErbB4 phosphorylation and
total ErbB4 protein levels, immunoblotting was performed
antibodies against phospho-ErbB4 (Tyr1284) (Cell
Signaling) and HA-tag (Abcam), respectively. The two
amino acid substitutions, p. Arg927Gln and p.
Arg1275Trp, showed a clearly reduced autophosphoryla-
tion of ErbB4 (Figure 2). On the basis of these genetic
and functional data, we concluded that the two mutations
are causative mutations for ALS (ALS19).
This study revealed that a reduced autophosphorylation
of ErbB4 upon NRG-1 stimulation is involved in the path-
ogenesis of ALS. Erbb4 is specifically expressed in the soma
of large motor neurons of the rat spinal cord.16 The lack of
Erbb4 is embryonically lethal in mice, which displayed the
derangement of motor-neuron axon guidance and path-
finding during embryogenesis.17 Heterozygous-null mice
showed a reduced bodyweight and delayedmotor develop-
ment, and brain-specific conditional knock-out miceJournal of Human Genetics 93, 900–905, November 7, 2013 903
demonstrated reduced spontaneous motor activity and
grip strength of the hindlimbs.18 Mice lacking cysteine-
rich domain (CRD) isoforms of Nrg-1 (CRD-NRG-1/) die
perinatally as a result of respiratory failure, lack detectable
limbmovement, and exhibit a loss of ~60% of spinalmotor
neurons.19 Similarly, motor and sensory neuron-specific
conditional Nrg-1 knockout mice die at birth and showed
marked retraction of motor-neuron axons.20 Furthermore,
a decrease in the amount of CRD-NRG-1 has been detected
in the spinal motor neurons in FALS and SALS individuals
and Sod1 mutant mice at disease onset,21 raising the pos-
sibility that disruption of the NRG-ErbB pathway is
commonly involved in the motor-neuron degeneration
underlying ALS. This study provides insight into ALS path-
ogenesis and is expected to pave the way for the develop-
ment of innovative therapeutic strategies such as using
NRGs or their agonists to upregulate ErbB4 functions.
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